---
title: "Beam Therapeutics (BEAM): news, pipeline and catalysts"
url: "https://aibio.space/companies/beam-therapeutics/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "Beam Therapeutics news for investors: Beam Therapeutics develops base editing medicines that change single letters of DNA, with lead programs in sickle cell…"
---

Desk view · Opinion · Updated Oct 22, 2026

## Beam's base editing works in the clinic; selling it is the next test

Beam has two programs near registration and clean biology in both. The bigger questions are commercial: whether risto-cel can win patients in a slow sickle cell market, and whether the debt-backed runway holds if milestones slip.

Read the full desk view

aibio.space Investor Rank · Opinion

**6** /10 Neutral view

Two base editing programs are near registration with clean data, but risto-cel faces a slow sickle cell market and the runway depends on more debt draws.

- **Technology**: 1/2

- **Odds**: 1/2

- **Balance sheet**: 1/2

- **Risk**: 1/2

- **Momentum**: 2/2

Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. [How the rank works](https://aibio.space/disclosures/#rank).

- **Technology**: **Strong early biology.** Risto-cel lifted fetal hemoglobin above 60%, and BEAM-302 cut mutant Z-AAT 84% at 60 mg.

- **Odds**: **Good at filing, early elsewhere.** Base rates put approval near 91% once a BLA is filed, but BEAM-301 and BEAM-304 are in phase 1/2.

- **Balance sheet**: **Funded with debt support.** $1.15 billion at June 30, 2026, and runway into mid-2029 depends on more Sixth Street draws.

- **Main risk**: **Commercial uptake.** Risto-cel would launch second, behind Casgevy, in a market slowed by chemotherapy conditioning.

- **Watch next**: **Risto-cel filing.** Updated BEACON data and a possible BLA are due by year-end 2026.

## Top news on Beam

## Dates

**2026**
Initial BEAM-301 clinical data in glycogen storage disease Ia [Source](https://www.sec.gov/Archives/edgar/data/0001745999/000119312526331522/beam-ex99_1.htm)

**By year-end 2026**
Updated BEACON data for risto-cel [Source](https://www.sec.gov/Archives/edgar/data/0001745999/000119312526331522/beam-ex99_1.htm)

**As early as year-end 2026**
Risto-cel BLA submission [Source](https://www.sec.gov/Archives/edgar/data/0001745999/000119312526331522/beam-ex99_1.htm)

**Ongoing**
Enrollment of about 50 patients in the BEAM-302 registrational cohort [Source](https://www.globenewswire.com/news-release/2026/09/08/3357432/0/en/beam-therapeutics-presents-updated-clinical-data-from-the-phase-1-2-trial-of-beam-302-in-alpha-1-antitrypsin-deficiency-aatd-at-the-european-respiratory-society-ers-congress-2026.html)

## The money

$1.15 billion in cash, cash equivalents and marketable securities at June 30, 2026 (Q2 2026). With an expected additional $200 million from the Sixth Street facility, runway guided into mid-2029. [Source](https://www.sec.gov/Archives/edgar/data/0001745999/000119312526331522/beam-ex99_1.htm)

## Risks on the record

- Most of the $500 million Sixth Street facility is tied to risto-cel milestones; the debt carries about 10% interest and first-priority liens on substantially all assets. [Source](https://beamtherapeutics.gcs-web.com/news-releases/news-release-details/beam-therapeutics-announces-500-million-strategic-financing)
- One BEAM-302 patient with liver disease had a transient grade 3 ALT/AST rise at 60 mg. [Source](https://www.globenewswire.com/news-release/2026/09/08/3357432/0/en/beam-therapeutics-presents-updated-clinical-data-from-the-phase-1-2-trial-of-beam-302-in-alpha-1-antitrypsin-deficiency-aatd-at-the-european-respiratory-society-ers-congress-2026.html)
- Risto-cel would compete with Casgevy, already approved in the U.S. for patients aged 2 and older. [Source](https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-us-fda-approval-expanded-use-casgevyr-treatment)

## Questions investors ask

### What is aibio.space's Investor Rank for Beam Therapeutics?

6 out of 10, our neutral view. Two base editing programs are near registration with clean data, but risto-cel faces a slow sickle cell market and the runway depends on more debt draws. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. [Source](https://aibio.space/disclosures/#rank)

### When will Beam Therapeutics file for approval of risto-cel?

Beam says it expects to submit a BLA for risto-cel in sickle cell disease as early as year-end 2026, with updated BEACON data by then. Dosing is complete for all adult and adolescent patients in the trial. [Source](https://www.sec.gov/Archives/edgar/data/0001745999/000119312526331522/beam-ex99_1.htm)

### What did BEAM-302 show at ERS 2026?

At 60 mg, mean total AAT reached 14.4 micromolar in lung disease patients and 13.5 in liver disease patients, above the 11 micromolar protective level the company cites. Mutant Z-AAT fell 84%. [Source](https://www.globenewswire.com/news-release/2026/09/08/3357432/0/en/beam-therapeutics-presents-updated-clinical-data-from-the-phase-1-2-trial-of-beam-302-in-alpha-1-antitrypsin-deficiency-aatd-at-the-european-respiratory-society-ers-congress-2026.html)

### How much cash does Beam Therapeutics have?

Beam reported $1.15 billion in cash, cash equivalents and marketable securities at June 30, 2026. It says that plus an expected additional $200 million from Sixth Street funds operations into mid-2029. [Source](https://www.sec.gov/Archives/edgar/data/0001745999/000119312526331522/beam-ex99_1.htm)

### What is the Beam Therapeutics Sixth Street loan?

It is a $500 million senior secured credit facility announced in February 2026, with $100 million funded at close and up to $300 million tied to risto-cel milestones. Interest is about 10% a year and it matures in early 2033. [Source](https://beamtherapeutics.gcs-web.com/news-releases/news-release-details/beam-therapeutics-announces-500-million-strategic-financing)

### Is Beam Therapeutics working on PKU?

Yes. The FDA cleared Beam's IND for BEAM-304 in phenylketonuria on June 18, 2026. The phase 1/2 trial will start with patients who carry the R408W mutation. [Source](https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-announces-clearance-investigational-new-drug-0)

### What is Beam Therapeutics's market cap?

We do not publish live share prices. In its annual report, Beam Therapeutics Inc. put the market value of shares held by non-affiliates (public float) at $1.70 billion as of Jun 30, 2025. Source

### Is Beam Therapeutics a smaller reporting company?

SEC records list Beam Therapeutics Inc.'s filer category as: Large accelerated filer. Source

### Where is Beam Therapeutics headquartered?

SEC records list its business address as 26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139. Source

### When does Beam Therapeutics's fiscal year end?

Beam Therapeutics Inc.'s fiscal year ends on December 31, per SEC records. Source

### What did Beam Therapeutics last file with the SEC?

Its most recent filing in our record is a 10-Q filed 2026-08-04. All of its filings are on SEC EDGAR. [Source](https://www.sec.gov/Archives/edgar/data/1745999/000119312526331541/beam-20260630.htm)

### What was Beam Therapeutics called before?

SEC records list these former names: Beam Therapeutics Inc.. Source

### What industry is Beam Therapeutics in?

Its SEC industry code (SIC 2836) is Biological Products, (No Diagnostic Substances). Source

## Legal and investor matters

Checked against Beam Therapeutics filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026.

Beam's 10-Q filed 2026-08-04 (Part II, Item 1) states that Beam is not currently subject to any material legal proceedings. [Source](https://www.sec.gov/Archives/edgar/data/1745999/000119312526331541/beam-20260630.htm)

1. 2026-02-24 Financing Beam signs senior secured term loan of up to $500 million with Sixth Street On 2026-02-24 Beam Therapeutics entered a financing agreement with Sixth Street Lending Partners as administrative and collateral agent. The senior secured term loan facility is for up to $500 million, with $100 million drawn at closing and further draws tied to FDA acceptance and approval of the risto-cel BLA and other conditions. The loan matures 2033-02-24 and is secured by substantially all assets of Beam and its material subsidiaries. [Beam Form 8-K](https://www.sec.gov/Archives/edgar/data/1745999/000119312526065191/beam-20260224.htm)
2. 2025-12-08 Other Beam receives $255.1 million as Bristol Myers Squibb buys Orbital Therapeutics Bristol-Myers Squibb completed its acquisition of Orbital Therapeutics on 2025-12-08. Beam held 75 million Orbital shares, a fully diluted stake of about 17%, which were converted into $255.1 million in closing cash. Beam may also receive up to about $26.3 million more if certain escrows are released. Beam said it planned to update its cash runway at the 2026 J.P. Morgan Healthcare Conference. [Beam Form 8-K](https://www.sec.gov/Archives/edgar/data/1745999/000119312525316043/beam-20251208.htm)
3. 2025-07-01 Other Beam acquires early-stage company for shares and up to $89 million in milestones On 2025-07-01 Beam entered a merger agreement to acquire an early-stage life sciences company that its 8-K does not name. Beam agreed to issue 403,128 shares of common stock upfront and up to $89,000,000 in milestone payments, payable in cash or shares at Beam's discretion. Based on the 2025-06-30 closing price of $17.01, the maximum number of milestone shares was 5,232,216. [Beam Form 8-K](https://www.sec.gov/Archives/edgar/data/1745999/000095017025093906/beam-20250701.htm)
4. 2025-03-10 Financing Beam prices public offering at $28.48 per share, about $469.7 million net On 2025-03-10 Beam agreed to sell 16,151,686 shares of common stock at $28.48 per share, plus pre-funded warrants for 1,404,988 shares at $28.47 each, in an underwritten offering led by J.P. Morgan, Jefferies, Cantor Fitzgerald, Citigroup and Wells Fargo. All securities were sold by Beam. The 8-K states net proceeds of approximately $469.7 million. [Beam Form 8-K](https://www.sec.gov/Archives/edgar/data/1745999/000119312525051072/d930164d8k.htm)

## Pipeline

| Program | Indication | Stage |
|---|---|---|
| Risto-cel (ristoglogene autogetemcel, formerly BEAM-101) | Sickle cell disease | Phase 1/2 BEACON complete dosing; BLA planned as early as year-end 2026 [Source](https://www.sec.gov/Archives/edgar/data/0001745999/000119312526331522/beam-ex99_1.htm) |
| BEAM-302 | Alpha-1 antitrypsin deficiency | Phase 1/2 with registrational expansion cohort (accelerated approval path) [Source](https://www.globenewswire.com/news-release/2026/09/08/3357432/0/en/beam-therapeutics-presents-updated-clinical-data-from-the-phase-1-2-trial-of-beam-302-in-alpha-1-antitrypsin-deficiency-aatd-at-the-european-respiratory-society-ers-congress-2026.html) |
| BEAM-301 | Glycogen storage disease Ia (R83C) | Phase 1/2 [Source](https://www.sec.gov/Archives/edgar/data/0001745999/000119312526331522/beam-ex99_1.htm) |
| BEAM-304 | Phenylketonuria (R408W first) | IND cleared; phase 1/2 start-up [Source](https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-announces-clearance-investigational-new-drug-0) |
| BEAM-103 (anti-CD117 antibody) | Non-chemotherapy conditioning | Phase 1 healthy volunteers completed [Source](https://www.sec.gov/Archives/edgar/data/0001745999/000119312526331522/beam-ex99_1.htm) |

Opinion · Devil's advocate

## Fact-check-o-meter

Some gaps

Beam's messaging mostly matches its filings, but the runway and the BEAM-302 safety story need the fine print

Beam's releases and its second-quarter 10-Q tell the same basic story, and the 10-Q discloses no material legal proceedings. The gaps are in framing: the mid-2029 runway counts $200 million of debt that only unlocks on risto-cel regulatory milestones, and the September BEAM-302 release left out the multi-dose cohort where the 10-Q reports a Grade 4 liver enzyme rise. The AATD data are open-label biomarker results, and the 10-Q and the September release report 60 mg AAT levels with different assays (LC-MS versus turbidimetry), so the two means are not directly comparable.

1. Press release vs filing · weight medium Runway leans on milestone-gated debt **The company said:** "together with an additional $200 million expected to be drawn from the company's facility with Sixth Street, will fund anticipated operating expenses and capital expenditure requirements into mid-2029" [source](https://www.sec.gov/Archives/edgar/data/0001745999/000119312526331522/beam-ex99_1.htm) **The record says:** The 10-Q says the facility offers "a potential additional $ 100 million draw upon the acceptance by the U.S. Food and Drug Administration, or FDA, of the Company's biologics license application, or BLA, submission for risto-cel prior to a certain date" and a second $100 million "upon the FDA's approval of the risto-cel BLA prior to a certain date". It reports an effective interest rate of 10.5% at June 30, 2026, and its own going-concern horizon is that cash "will be sufficient to fund its operations for at least the next 12 months". [source](https://www.sec.gov/Archives/edgar/data/1745999/000119312526331541/beam-20260630.htm) **Our view:** The release presents the $200 million as expected, while the 10-Q makes both tranches depend on FDA accepting and then approving risto-cel by dates it does not disclose. If the BLA slips, part of the mid-2029 runway goes with it, so the runway is better read as tied to the risto-cel timeline.
2. Press release vs filing · weight medium BEAM-302 safety summary leaves out the redosed patients **The company said:** "Data from patients in the multi-dose cohort (n=3) and the Part A expansion cohort (n=6) were not included." [source](https://www.globenewswire.com/news-release/2026/09/08/3357432/0/en/beam-therapeutics-presents-updated-clinical-data-from-the-phase-1-2-trial-of-beam-302-in-alpha-1-antitrypsin-deficiency-aatd-at-the-european-respiratory-society-ers-congress-2026.html) **The record says:** The 10-Q, describing the February 10, 2026 data cut, states: "In the multi-dose cohort (n=3), following the second dose of BEAM-302, patients experienced Grade 2 IRRs, one patient had Grade 4 ALT and Grade 3 AST elevations, and one patient had a Grade 2 ALT elevation." It adds that the elevations were asymptomatic and did not require treatment. [source](https://www.sec.gov/Archives/edgar/data/1745999/000119312526331541/beam-20260630.htm) **Our view:** The September release says plainly that the multi-dose and Part A expansion cohorts were not included and describes single-dose BEAM-302 as well tolerated, which the 10-Q data also support. But a reader of the release alone would not learn that one of the three patients in the multi-dose cohort had a Grade 4 ALT elevation after the second dose, which matters if some patients ever need a second dose to reach target levels.
3. Science · weight medium 60 mg AAT figures in the 10-Q and the September release use different assays **The company said:** "mean and median were 14.4 µM and 15.2 µM, respectively" [source](https://www.globenewswire.com/news-release/2026/09/08/3357432/0/en/beam-therapeutics-presents-updated-clinical-data-from-the-phase-1-2-trial-of-beam-302-in-alpha-1-antitrypsin-deficiency-aatd-at-the-european-respiratory-society-ers-congress-2026.html) **The record says:** The 10-Q reports the February 10, 2026 cut for the 60 mg Part A cohort (n=6): the steady-state circulating total AAT mean (LC-MS) "was 16.1 µM in the 60 mg cohort (follow-up ranging from 5-12 months)". Its footnotes define steady state as running from Day 28 to Month 12 (or the last visit if earlier) and say levels were measured with a liquid chromatography-mass spectrometry assay. The September release, for the June 24, 2026 cut, gives a mean of 14.4 µM, defines steady state as running from Day 28 to the patient's last visit, says "Circulating total AAT levels were measured using turbidimetry", and states "Data were consistent with topline results announced in March 2026." [source](https://www.sec.gov/Archives/edgar/data/1745999/000119312526331541/beam-20260630.htm) **Our view:** Both figures sit above the 11 µM protective threshold the company uses, and the company calls the data consistent with March 2026. Because the assay, the follow-up window and the data cut all differ, the 14.4 µM figure cannot be read as a decline from 16.1 µM. The release does not say how turbidimetry and LC-MS results compare, which matters for the 12-month AAT biomarker the registrational cohort will be judged on.
4. Science · weight medium Registrational AATD cohort is open-label and judged on a biomarker **The company said:** "The cohort is designed to support a potential accelerated approval path in the United States." [source](https://www.sec.gov/Archives/edgar/data/0001745999/000119312526331522/beam-ex99_1.htm) **The record says:** ClinicalTrials.gov lists NCT06389877 as single group, allocation not applicable, masking none, with an estimated 192 participants and primary outcomes including "Mean total and functional AAT in blood" over 1 year. The 10-Q says the plan is "a primary endpoint of AAT biomarkers evaluated over 12 months" in about 50 patients in "a pivotal expansion of the ongoing open-label Phase 1/2 trial". [source](https://clinicaltrials.gov/study/NCT06389877) **Our view:** An accelerated approval on blood AAT levels would rest on a surrogate, with no placebo arm and no lung function endpoint in the registrational cohort. That is a normal path for a rare disease, but it leaves the clinical lung benefit to be shown later.
5. Science · weight low Risto-cel data come from a small single-arm trial **The company said:** "Ristoglogene autogetemcel (risto-cel, formerly known as BEAM-101) is an investigational autologous cell therapy with a potential best-in-class profile for the treatment of sickle cell disease (SCD)." [source](https://www.sec.gov/Archives/edgar/data/0001745999/000119312526331522/beam-ex99_1.htm) **The record says:** ClinicalTrials.gov lists BEACON (NCT05456880) as single group with masking none. The 10-Q states: "one patient died four months after risto-cel infusion due to respiratory failure that was determined by the investigator to be likely related to busulfan conditioning and deemed unrelated to risto-cel." [source](https://clinicaltrials.gov/study/NCT05456880) **Our view:** Best-in-class is the company's own description. BEACON is registered as a single group study, so any comparison with other sickle cell therapies is cross-trial. The 10-Q discloses a death that the investigator judged likely related to busulfan conditioning and unrelated to risto-cel.
6. Legal and disclosure record · weight low No litigation or enforcement disclosed **The record says:** Part II, Item 1 of the 10-Q for the quarter ended June 30, 2026: "We are not currently subject to any material legal proceedings." [source](https://www.sec.gov/Archives/edgar/data/1745999/000119312526331541/beam-20260630.htm) **Our view:** No securities litigation or enforcement disclosed in the latest filing. The risk factors flag possible patent challenges in base editing as a general risk, not as a pending case.

Documents we compared

- [Beam Q2 2026 results press release (8-K Exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/0001745999/000119312526331522/beam-ex99_1.htm) 2026-08-04
- [Beam Form 10-Q for the quarter ended June 30, 2026](https://www.sec.gov/Archives/edgar/data/1745999/000119312526331541/beam-20260630.htm) 2026-08-04
- [Beam BEAM-302 ERS Congress 2026 data release](https://www.globenewswire.com/news-release/2026/09/08/3357432/0/en/beam-therapeutics-presents-updated-clinical-data-from-the-phase-1-2-trial-of-beam-302-in-alpha-1-antitrypsin-deficiency-aatd-at-the-european-respiratory-society-ers-congress-2026.html) 2026-09-08
- [ClinicalTrials.gov NCT06389877 (BEAM-302)](https://clinicaltrials.gov/study/NCT06389877) 2026-10-05
- [ClinicalTrials.gov NCT05456880 (BEACON, risto-cel)](https://clinicaltrials.gov/study/NCT05456880) 2025-12-16

This is opinion. We compare the company's own announcements with its filings and the scientific record, and link every source. It is not an allegation of wrongdoing and not investment or legal advice. Legal items list only matters disclosed in filings or by courts and regulators. Checked Oct 23, 2026. Companies can respond through our [right of reply](https://aibio.space/reputation/#reply).

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:BEAM on TradingView](https://www.tradingview.com/symbols/NASDAQ-BEAM/).

## SEC filings and registration

- **SEC name**: Beam Therapeutics Inc.

- **CIK**: 1745999

- **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836)

- **US tickers**: BEAM (Nasdaq)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: Large accelerated filer

- **Business address**: 26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139

- **Phone**: 857-327-8775

- **Shares outstanding**: 103,287,665 as of 2026-07-28 (10-Q filed 2026-08-04)

- **Former names**: Beam Therapeutics Inc.

### Recent filings (8-K and 6-K are the company's own announcements)

- [10-Q](https://www.sec.gov/Archives/edgar/data/1745999/000119312526331541/beam-20260630.htm) filed 2026-08-04
- [8-K](https://www.sec.gov/Archives/edgar/data/1745999/000119312526331522/beam-20260804.htm) filed 2026-08-04
- [8-K](https://www.sec.gov/Archives/edgar/data/1745999/000119312526261693/beam-20260603.htm) filed 2026-06-08
- [10-Q](https://www.sec.gov/Archives/edgar/data/1745999/000119312526210338/beam-20260331.htm) filed 2026-05-07
- [8-K](https://www.sec.gov/Archives/edgar/data/1745999/000119312526210299/beam-20260507.htm) filed 2026-05-07
- [DEF 14A](https://www.sec.gov/Archives/edgar/data/1745999/000119312526161512/beam-20260417.htm) filed 2026-04-17
- [8-K](https://www.sec.gov/Archives/edgar/data/1745999/000119312526093914/beam-20260302.htm) filed 2026-03-05
- [10-K](https://www.sec.gov/Archives/edgar/data/1745999/000119312526065194/beam-20251231.htm) filed 2026-02-24

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001745999), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/beam-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Beam Therapeutics (BEAM): news, pipeline and catalysts", 2026-10-31, https://aibio.space/companies/beam-therapeutics/